Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

NCT05033769 · clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
82
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut fuer Frauengesundheit

Collaborators